Mark Selby
oncology Discovery
Bristol Meyers Scribb
Philippines
Biography
Mark has worked at Bristol-Myers Squibb and Medarex (before it was acquired by Bristol-Myers Squibb in 2009) for over 15 years, focusing his research on anti-PD-1, anti-PD-L1, anti-PD-1 + anti-CTLA-4, anti-LAG-3 and anti-GITR. He and his team have been responsible for moving preclinical antibody assets related to these targets, some of which are now approved for oncology indications. Prior to his work at Medarex/Bristol-Myers Squibb, Mark worked as a scientist at the biopharmaceutical company, Chiron, where he focused on vaccine research.
Research Interest
oncology Discovery
